Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02448810 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

115

Enrollment

INDUSTRY

Sponsor class

Stopped Based on overall benefit-risk assessment.

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: BAX69 + infusional 5-FU/LV
BIOLOGICAL: BAX69 + panitumumab
BIOLOGICAL: BAX69 + 5-FU/LV
BIOLOGICAL: BAX69 + panitumumab
DRUG: Standard of Care
BIOLOGICAL: Standard of Care

Sponsor

Baxalta now part of Shire